| Autor: |
M.-O. Benoît, L. Mauge, J.-L. Paul |
| Rok vydání: |
2010 |
| Předmět: |
|
| Zdroj: |
Immuno-analyse & Biologie Spécialisée. 25:56-61 |
| ISSN: |
0923-2532 |
| DOI: |
10.1016/j.immbio.2010.01.004 |
| Popis: |
Summary Background Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-β (TGFβ) superfamily. The growing interest for its prognostic value in acute coronary syndromes (ACS) and pulmonary embolism lead us to evaluate a recently commercialised immunoenzymatic Elisa kit. Methods The DuoSet ® Elisa kit (R&D Systems ® ) was evaluated according to the Societe francaise de biologie clinique (SFBC) validation protocol. Pre-analytical conditions were tested. GDF-15 was quantified in two groups: “healthy” individuals and patients with troponin greater than 0,15 μg/L. Results The method was validated. Heparinated plasma at a one-eighth dilution was selected for the study. The stability of GDF-15 allows several freeze/thaw cycles. Medians of the GDF-15 levels in the two populations (827 ng/L versus 3268 ng/L) were significantly different. Conclusion The DuoSet ® Elisa kit can be used to quantify GDF-15 in human serum and plasma. This will allow us to study GDF-15 prognostic interest in different clinical settings like ACS and pulmonary embolism. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect